SEMA4D and melanoma: To understand the expression of Sema4D in melanoma resistance to anti-PD-1, B16-F10 resistant cell lines was established, after administered 50 ng/ml nivolumab, the killing ability of nivolumab was significantly weaker than that of B16-F10 cell lines, this means that resistant cell lines are established successfully.